|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net (decrease) increase in net assets from operations | |||
| Adjustments to reconcile net (decrease) increase in net assets to net cash provided by (used in) operating activities: | |||
| Investments in portfolio companies | |||
| Proceeds from sale of portfolio investments | |||
| Proceeds from loan repayments | |||
| Net realized loss (gain) on portfolio investments | |||
| Change in unrealized appreciation/depreciation on investments | |||
| Deferred tax expense (benefit) | |||
| Amortization | |||
| Original issue discount accretion | |||
| Non-cash conversion of debenture interest | |||
| Non-cash conversion of loan modification fee | |||
| Change in interest receivable allowance | |||
| Changes in operating assets and liabilities: | |||
| Decrease (increase) in interest receivable | |||
| Decrease in other assets | |||
| Decrease (increase) in prepaid income taxes | |||
| Increase (decrease) in accounts payable and accrued liabilities | |||
| (Decrease) increase in due to investment adviser | |||
| (Decrease) increase in capital gains incentive fees payable | |||
| (Decrease) increase in deferred revenue | |||
| Total adjustments | |||
| Net cash provided by (used in) operating activities | |||
| Cash flows from financing activities: | |||
| Net proceeds from line of credit | |||
| Net (repayment of) proceeds from line of credit | |||
| Payment of cash dividend | |||
| Net cash (used in) provided by financing activities | |||
| Net increase (decrease) in cash and cash equivalents | |||
| Cash and cash equivalents: | |||
| Beginning of year | |||
| End of year | |||
| Supplemental disclosure of non-cash financing activities | |||
| Fair value of common stock dividend declared | |||
| Cash dividend declared but not paid |
Loading...
